Clinical trials
Non Muscle Invasive Bladder Cancer clinical trials
Below are recruiting non muscle invasive bladder cancer clinical trials, each written for real people, not researchers. We’re tracking 142 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05453682Recruiting
Radiation plus chemotherapy to preserve the bladder
This study tests whether a shorter, more focused radiation plan given at the same time as chemotherapy can control muscle-invasive bladder cancer while keeping the bladder. You may be offered bladder-preserving treatment if your cancer stage and health conditions fit the study rules.
SeoulAges 20 years+ - NCT06108492RecruitingPhase 1
A new bladder cancer drug given directly into the bladder
This study tests a new drug, SHR-2005, given directly into the bladder through a catheter. It is for people with intermediate- or high-risk bladder cancer that hasn't spread into the muscle, and aims to see if it is safe and how well it works.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07602010Recruiting
Comparing CT and MRI scans for bladder cancer staging
This trial compares two imaging methods—CT and MRI scans—to see which one better shows how far bladder cancer has spread before surgery. If you have newly diagnosed bladder cancer and are planning surgery, this study may help doctors choose the best imaging for your care.
OsloAges 18 years+ - NCT07566156RecruitingPhase 3
New drug combination vs. radiation for bladder cancer preservation
This trial tests whether two drugs (enfortumab vedotin and pembrolizumab) work better than radiation with chemotherapy for muscle-invasive bladder cancer. The goal is to treat your cancer while keeping your bladder instead of removing it.
Santa Barbara, CaliforniaAges 18 years+ - NCT05790850Recruiting
Mindfulness and exercise plan before bladder surgery
This study tests whether a structured mindfulness and high-intensity exercise program before radical bladder surgery can help patients improve health and recovery. You may be asked to use monitoring devices and complete questionnaires during the study.
Charlottesville, VirginiaAges 18–90 - NCT06732531RecruitingPhase 1/Phase 2
Testing a new drug for high-risk bladder cancer that came back after BCG
This clinical trial tests a new drug, BH011, for people with high-risk, non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. The goal is to see if the drug is safe and works well when given directly into the bladder, as an alternative to bladder removal surgery.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07494864Recruiting
Urinary tract health and microbiome study
This study looks at how bacteria and the immune system affect the lower urinary tract. It includes healthy volunteers and people with various urinary conditions, like infections or bladder pain.
Zurich, Canton of ZurichAges 18 years+ - NCT07483970RecruitingPhase 1
JL19001 alone or with BCG for high-risk non-muscle invasive bladder cancer
This trial tests a new drug called JL19001, given alone or with BCG (a standard bladder cancer treatment), for people with high-risk bladder cancer that hasn't spread into the bladder muscle. The goal is to see if it can help prevent the cancer from coming back or getting worse.
Chengdu, SichuanAges 18 years+ - NCT04724928RecruitingPhase 2
PET-CT scan to guide bladder cancer treatment decisions
This Phase 2 study checks whether an FDG PET-CT scan can help doctors better predict bladder cancer risk and adjust treatment. You may still get standard bladder cancer care, but the study uses the scan results to help decide how aggressive treatment should be.
GhentAges 18 years+ - NCT06186414RecruitingPhase 1
SIM0237 with or without BCG for bladder cancer
This trial tests a new drug, SIM0237, alone or with BCG, for people with a type of bladder cancer called non-muscle invasive bladder cancer (NMIBC) that did not respond to BCG treatment. The goal is to see if it is safe and works against the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07475806RecruitingPhase 2
Bladder-sparing drug combo for muscle-invasive bladder cancer
This study tests two drugs, enfortumab vedotin and pembrolizumab, to see if they can help people with muscle-invasive bladder cancer avoid removing their bladder. The drugs are given before the standard surgery to possibly shrink the tumor and improve outcomes.
Little Rock, ArkansasAges 18 years+ - NCT07480356RecruitingPhase 3
Testing a new bladder cancer treatment (TARA-002) vs standard chemo
This trial compares a new medicine called TARA-002, given directly into the bladder, to the doctor's choice of standard chemotherapy. It is for people with a high-grade, non-muscle invasive bladder cancer that has not been treated with BCG or has not had BCG recently.
Queen Creek, ArizonaAges 18 years+ - NCT07475403RecruitingPhase 2
Immunotherapy guided by urine DNA for high risk bladder cancer
This trial tests a new immunotherapy approach for people with a very high risk type of bladder cancer that hasn't spread into the muscle layer. The treatment is guided by a special urine test that looks for tumor DNA, and it may help if surgery cannot remove all the cancer or you choose not to have your bladder removed.
TianjinAges 18 years+ - NCT07474519RecruitingPhase 4
Studying position and dwell time for BCG bladder cancer treatment
This trial tests whether changing your position while receiving BCG treatment (a liquid medicine placed directly into the bladder) can help it work better. You will wear a fitness tracker for a few days to monitor activity.
Columbus, OhioAges 18 years+ - NCT07468851RecruitingPhase 1/Phase 2
Study of HS-10566 for high-risk bladder cancer that hasn't spread into muscle
This study tests a new treatment called HS-10566 for people with a type of bladder cancer that has not reached the muscle layer and is considered high-risk, where the usual treatments have not worked or were not an option. It aims to control the cancer and avoid the need for removing the bladder.
BeijingAges 18 years+ - NCT07424560Recruiting
Bladder Cancer DNA Testing Study
This study looks for specific DNA changes in bladder cancer tumors using a precise test. It aims to better understand the disease and may help guide future treatment choices.
Lanzhou, GansuAges 18 years+ - NCT07420517RecruitingPhase 2
Dutasteride for low-grade bladder cancer
This trial tests if the drug dutasteride can help people with a slow-growing type of bladder cancer that hasn't spread into the muscle wall. It may be an option for those not receiving other standard treatments like BCG therapy or chemotherapy directly into the bladder.
Québec, QuebecAges 18 years+ - NCT06696794RecruitingPhase 3
Testing mitomycin before surgery for high-risk bladder cancer
This trial tests whether giving mitomycin directly into the bladder before surgery can help people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this approach is safe and effective at preventing cancer from coming back.
Wuhan, HubeiAges 18–75 - NCT07339761Recruiting
Sexual health support for bladder cancer patients
This study from the University of Aarhus looks at ways to support sexual health in people who have been treated for bladder cancer. If you are a Danish-speaking adult who had bladder cancer treatment about a year ago and have noticed changes in sexual function, you may be able to join.
AarhusAges 18 years+ - NCT07322263RecruitingPhase 2
Gemcitabine and docetaxel for bladder cancer that returned after BCG
This trial tests a combination of two chemotherapy drugs (gemcitabine and docetaxel) given directly into the bladder to treat high-risk non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. It's for people who cannot or choose not to have their bladder removed.
Iowa City, IowaAges 18–99 - NCT07309445Recruiting
Real-world use of TAR-200 for non-muscle invasive bladder cancer
This study looks at how patients with non-muscle invasive bladder cancer are using TAR-200 in everyday medical care. It aims to understand treatment patterns and outcomes outside of a clinical trial.
Birmingham, AlabamaAges 18 years+ - NCT07302230Recruiting
Home exercise app for bladder cancer patients
This trial tests whether a home-based physical activity program using a smartphone app helps people with non-muscle invasive bladder cancer become more active compared to a health education group. It's designed for those who are not very active and want to improve their health.
Seattle, WashingtonAges 18 years+ - NCT07296705RecruitingPhase 2
New drug combo to save the bladder in HER2-positive bladder cancer
This trial tests combining two newer drugs (zanidatamab and tislelizumab) with standard chemotherapy before bladder surgery. The goal is to shrink the tumor so the bladder can be saved instead of removed.
Fuzhou, FujianAges 18–85 - NCT06735287Recruiting
Bladder-sparing treatment for large bladder cancer
This trial tests a combination of chemotherapy and immunotherapy to treat large, non-invasive bladder cancer before and after surgery. It aims to avoid removing the bladder while still effectively treating the cancer.
Nanjing, JiangsuAges 18–80
Hear when a new Non Muscle Invasive Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for non muscle invasive bladder cancer?
- Yes. Clin2 currently lists 142 recruiting non muscle invasive bladder cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a non muscle invasive bladder cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a non muscle invasive bladder cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- High Risk Non-muscle Invasive Bladder Cancer
- Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
- Muscle Invasive Bladder Cancer (MIBC)
- Non-Muscle Invasive Bladder Urothelial Carcinoma
- Non-Muscle Invasive Bladder Neoplasms
- Non-Muscle Invasive Bladder Carcinoma
- Recurrent Non-Muscle Invasive Bladder Carcinoma
- Non Small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.